VCA Inc.
VCA ANTECH INC (Form: 10-Q, Received: 08/09/2007 13:30:51)
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
     
þ   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2007
     
o   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 001-16783
 
VCA ANTECH, INC.
(Exact name of registrant as specified in its charter)
     
Delaware   95-4097995
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)
12401 West Olympic Boulevard
Los Angeles, California 90064-1022

(Address of principal executive offices)
(310) 571-6500
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes þ      No o .
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer þ                     Accelerated filer o                     Non-accelerated filer o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o      No þ .
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: common stock, $0.001 par value 83,830,485 shares as of August 6, 2007.
 
 

 


 

VCA ANTECH, INC.
FORM 10-Q
JUNE 30, 2007
TABLE OF CONTENTS
             
        Page
        Number
  Financial Information        
 
           
  Financial Statements (Unaudited)        
 
           
 
  Condensed, Consolidated Balance Sheets as of June 30, 2007 and December 31, 2006     1  
 
           
 
  Condensed, Consolidated Income Statements for the Three and Six Months Ended June 30, 2007 and 2006     2  
 
           
 
  Condensed, Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2007 and 2006     3  
 
           
 
  Notes to Condensed, Consolidated Financial Statements     4  
 
           
  Management’s Discussion and Analysis of Financial Condition and Results of Operations     12  
 
           
  Quantitative and Qualitative Disclosures About Market Risk     27  
 
           
  Controls and Procedures     27  
 
           
  Other Information        
 
           
  Legal Proceedings     27  
 
           
  Risk Factors     27  
 
           
  Unregistered Sales of Equity Securities and Use of Proceeds     27  
 
           
  Defaults Upon Senior Securities     27  
 
           
  Submission of Matters to a Vote of Security Holders     28  
 
           
  Other Information     28  
 
           
  Exhibits     28  
 
           
 
  Signature     29  
 
           
 
  Exhibit Index     30  
  EXHIBIT 31.1
  EXHIBIT 31.2
  EXHIBIT 32.1

 


Table of Contents

PART I.   FINANCIAL INFORMATION
ITEM 1.   FINANCIAL STATEMENTS
VCA ANTECH, INC. AND SUBSIDIARIES
CONDENSED, CONSOLIDATED BALANCE SHEETS
As of June 30, 2007 and December 31, 2006
(Unaudited)
(In thousands, except par value)
                 
    June 30,     December 31,  
    2007     2006  
ASSETS
 
               
Current assets:
               
Cash and cash equivalents
  $ 62,107     $ 45,104  
Trade accounts receivable, less allowance for uncollectible accounts of $11,131 and $11,195 at June 30, 2007 and December 31, 2006, respectively
    48,071       44,491  
Inventory
    20,832       21,420  
Prepaid expenses and other
    15,617       13,492  
Deferred income taxes
    16,988       14,935  
Prepaid income taxes
    579       13,523  
 
           
Total current assets
    164,194       152,965  
Property and equipment, less accumulated depreciation and amortization of $121,212 and $111,165 at June 30, 2007 and December 31, 2006, respectively
    192,081       166,033  
Other assets:
               
Goodwill
    833,336       625,748  
Other intangible assets, net
    17,756       16,293  
Deferred financing costs, net
    1,636       979  
Other
    12,003       9,939  
 
           
Total assets
  $ 1,221,006     $ 971,957  
 
           
 
               
LIABILITIES AND STOCKHOLDERS’ EQUITY
 
               
Current liabilities:
               
Current portion of long-term obligations
  $ 7,554     $ 6,648  
Accounts payable
    25,307       23,328  
Accrued payroll and related liabilities
    36,873       33,864  
Other accrued liabilities
    41,838       30,961  
 
           
Total current liabilities
    111,572       94,801  
Long-term obligations, less current portion
    540,658       384,067  
Deferred income taxes
    44,652       39,804  
Other liabilities
    11,855       13,294  
Minority interest
    10,348       9,686  
Commitments and contingencies
               
Preferred stock, par value $0.001, 11,000 shares authorized, none outstanding
           
Stockholders’ equity:
               
Common stock, par value $0.001, 175,000 shares authorized, 83,821 and 83,560 shares outstanding as of June 30, 2007 and December 31, 2006, respectively
    84       84  
Additional paid-in capital
    282,521       275,013  
Retained earnings
    218,746       154,586  
Accumulated other comprehensive income
    570       622  
 
           
Total stockholders’ equity
    501,921       430,305  
 
           
Total liabilities and stockholders’ equity
  $ 1,221,006     $ 971,957  
 
           
The accompanying notes are an integral part of these condensed, consolidated financial statements.

1


Table of Contents

VCA ANTECH, INC. AND SUBSIDIARIES
CONDENSED, CONSOLIDATED INCOME STATEMENTS
For the Three and Six Months Ended June 30, 2007 and 2006
(Unaudited)
(In thousands, except per share amounts)
                                 
    Three Months Ended     Six Months Ended  
    June 30,     June 30,  
    2007     2006     2007     2006  
Revenue
  $ 300,305     $ 255,150     $ 565,450     $ 489,330  
Direct costs
    210,427       180,188       399,652       350,847  
 
                       
Gross profit
    89,878       74,962       165,798       138,483  
Selling, general and administrative expense
    22,043       19,484       43,516       38,369  
Write-down and loss (gain) sale of assets
    420       (85 )     542       (203 )
 
                       
Operating income
    67,415       55,563       121,740       100,317  
Interest expense, net
    6,671       5,927       12,444       12,239  
Other (income) expense
    172       (31 )     227       (97 )
 
                       
Income before minority interest and provision for income taxes
    60,572       49,667       109,069       88,175  
Minority interest in income of subsidiaries
    1,028       900       1,874       1,674  
 
                       
Income before provision for income taxes
    59,544       48,767       107,195       86,501  
Provision for income taxes
    23,697       19,214       43,035       27,289  
 
                       
Net income
  $ 35,847     $ 29,553     $ 64,160     $ 59,212  
 
                       
 
                               
Basic earnings per common share
  $ 0.43     $ 0.36     $ 0.77     $ 0.71  
 
                       
Diluted earnings per common share
  $ 0.42     $ 0.35     $ 0.75     $ 0.70  
 
                       
 
                               
Shares used for computing basic earnings per share
    83,742       83,118       83,674       82,966  
 
                       
Shares used for computing diluted earnings per share
    85,605       84,838       85,481       84,699  
 
                       
The accompanying notes are an integral part of these condensed, consolidated financial statements.

2


Table of Contents

VCA ANTECH, INC. AND SUBSIDIARIES
CONDENSED, CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Six Months Ended June 30, 2007 and 2006
(Unaudited)
(In thousands)
                 
    Six Months Ended  
    June 30,  
    2007     2006  
Cash flows from operating activities:
               
Net income
  $ 64,160     $ 59,212  
Adjustments to reconcile net income to net cash provided by operating activities:
               
Depreciation and amortization
    12,740       10,851  
Amortization of debt issue costs
    137       226  
Provision for uncollectible accounts
    2,110       2,976  
Write-down and loss (gain) on sale of assets
    542       (203 )
Share-based compensation
    2,300       1,445  
Excess tax benefit from exercise of stock options
    (2,680 )     (3,939 )
Minority interest in income of subsidiaries
    1,874       1,674  
Distributions to minority interest partners
    (1,364 )     (1,339 )
Deferred income taxes
    3,025       4,701  
Other
    (173 )     (561 )
Changes in operating assets and liabilities:
               
Accounts receivable
    (5,244 )     (6,182 )
Inventory, prepaid expenses and other assets
    45       (4,555 )
Accounts payable and other accrued liabilities
    (173 )     (6,480 )
Accrued payroll and related liabilities
    1,105       (526 )
Income taxes
    15,789       6,841  
 
           
Net cash provided by operating activities
    94,193       64,141  
 
           
Cash flows from investing activities:
               
Business acquisitions, net of cash acquired
    (203,322 )     (30,172 )
Real estate acquired in connection with business acquisitions
    (7,962 )     (1,781 )
Property and equipment additions
    (27,236 )     (15,067 )
Proceeds from sale of assets
    1,564       297  
Other
    (256 )     161  
 
           
Net cash used in investing activities
    (237,212 )     (46,562 )
 
           
Cash flows from financing activities:
               
Repayment of long-term obligations
    (4,224 )     (62,781 )
Proceeds from the issuance of long-term obligations
    160,000        
Payment of debt issue costs
    (794 )      
Proceeds from issuance of common stock under stock option plans
    2,360       3,576  
Excess tax benefit from exercise of stock options
    2,680       3,939  
 
           
Net cash provided by (used in) financing activities
    160,022       (55,266 )
 
           
Increase (decrease) in cash and cash equivalents
    17,003       (37,687 )
Cash and cash equivalents at beginning of period
    45,104       58,488  
 
           
Cash and cash equivalents at end of period
  $ 62,107     $ 20,801  
 
           
The accompanying notes are an integral part of these condensed, consolidated financial statements

3


Table of Contents

VCA ANTECH, INC. AND SUBSIDIARIES
NOTES TO CONDENSED, CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2007
(Unaudited)
1. General
     The accompanying unaudited, condensed, consolidated financial statements of our company, VCA Antech, Inc. and subsidiaries, have been prepared in accordance with generally accepted accounting principles in the United States for interim financial information and in accordance with the rules and regulations of the United States Securities and Exchange Commission. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles in the United States for annual financial statements as permitted under applicable rules and regulations. In the opinion of our management, all normal recurring adjustments considered necessary for a fair presentation have been included. The results of operations for the three and six months ended June 30, 2007, are not necessarily indicative of the results to be expected for the full year. For further information, refer to our consolidated financial statements and notes thereto included in our 2006 annual report on Form 10-K.
     The preparation of our condensed, consolidated financial statements in accordance with generally accepted accounting principles in the United States requires our management to make estimates and assumptions that affect the amounts reported in our condensed, consolidated financial statements and notes thereto. Actual results could differ from those estimates.
2. Acquisitions
     We acquired the following hospitals during the six months ended June 30, 2007:
         
Hospital acquisitions, excluding Healthy Pet (1)
    24  
Healthy Pet (1)
    44  
Acquisitions relocated into our existing animal hospitals
    (7 )
 
     
Total
    61  
 
     
 
(1)   Healthy Pet Corp. (“Healthy Pet”) was acquired on June 1, 2007.
Animal Hospital Acquisitions, Excluding Healthy Pet
     The following table summarizes the preliminary purchase price, including acquisition costs, paid by us for the 24 animal hospitals, excluding Healthy Pet, we acquired during the six months ended June 30, 2007, and the preliminary allocation of the purchase price (in thousands):
         
Preliminary Purchase Price:
       
Cash
  $ 47,055  
Liabilities assumed
    2,147  
 
     
Total
  $ 49,202  
 
     
 
       
Preliminary Allocation of the Purchase Price:
       
Tangible assets
  $ 2,293  
Identifiable intangible assets
    2,146  
Goodwill (1)
    44,763  
 
     
Total
  $ 49,202  
 
     
 
(1)   We expect that $43.1 million of the goodwill recorded for these acquisitions as of June 30, 2007 will be deductible for income tax purposes.

4


Table of Contents

Healthy Pet
     On June 1, 2007, we acquired Healthy Pet, which on that date operated 44 animal hospitals and a small laboratory that primarily serviced its own animal hospitals. This acquisition provided us with the opportunity to expand our animal hospital operations on the East Coast, particularly in Massachusetts, Connecticut, Virginia and Georgia. Our condensed, consolidated financial statements reflect the operating results of Healthy Pet since June 1, 2007.
     We acquired Healthy Pet for a preliminary purchase price of $169.3 million. The following table summarizes the preliminary purchase price and the preliminary allocation of the purchase price (in thousands):
         
Preliminary Purchase Price:
       
Cash paid to holders of Healthy Pet stock and debt, net of cash acquired
  $ 153,189  
Cash paid for professional services
    1,187  
Debt and capital leases assumed
    1,721  
Liabilities assumed
    10,262  
Liabilities for our plan to eliminate duplicate functions and to close certain animal hospitals
    2,952  
 
     
Total
  $ 169,311  
 
     
 
       
Preliminary Allocation of the Purchase Price:
       
Tangible assets
  $ 3,204  
Identifiable intangible assets
    1,348  
Goodwill (1)
    164,759  
 
     
Total
  $ 169,311  
 
     
 
(1)   As of June 30, 2007, we have not finalized the determination of the amount of goodwill that will be deductible for income tax purposes.
     The purchase price and the allocation of the purchase price is preliminary because certain events have not occurred or have not been completed or finalized, including but not limited to, the valuation of assets, including intangible assets, and liabilities, our plan to eliminate duplicate functions and close certain animal hospitals, the finalization of the purchase price, which is subject to normal terms and conditions, including working capital adjustments, and the final billings for professional services used in the acquisition.
Other Acquisition Payments
     In connection with certain acquisitions, we withheld a portion of the purchase price (“holdback”) as security for indemnification obligations of the sellers under the acquisition agreement. We paid $1.1 million to sellers for the unused portion of holdbacks during the six months ended June 30, 2007.
     During the six months ended June 30, 2007, we paid $745,000 to purchase the ownership interest in two partially-owned subsidiaries.
3. Long-Term Obligations and Interest Rate Swap Agreements
     On June 1, 2007, we amended our senior credit facility to allow for additional senior term notes in the amount of $160.0 million. The funds borrowed from the additional senior term notes were primarily used to fund the acquisition of Healthy Pet on June 1, 2007. The terms, including the interest rate, of these additional senior term notes are the same as the senior term notes existing prior to the amendment. Principal payments on the additional senior term notes are due quarterly in the amount of $400,000 and a final payment in the amount of $153.6 million is due on May 16, 2011. In connection with this amendment, we incurred debt issue costs in the amount of $794,000.

5


Table of Contents

     During the six months ended June 30, 2007, we entered into the following interest rate swap agreements to mitigate our exposure to the possibility of interest rates increasing:
         
Fixed interest rate
  4.95%   5.34%
Notional amount (in millions)
  $75.0   $100.0
Effective date
  4/30/2007   6/11/2007
Expiration date
  4/30/2009   12/31/2009
Counterparties
  Wells Fargo   Goldman Sachs
Qualifies for hedge accounting
  Yes   Yes
4. Goodwill and Other Intangible Assets
     Goodwill represents the excess of the cost of an acquired entity over the net of the fair value of identifiable assets acquired and liabilities assumed. The following table presents the changes in the carrying amount of our goodwill for the six months ended June 30, 2007 (in thousands):
                                 
            Animal     Medical        
    Laboratory     Hospital     Equipment     Total  
Balance as of December 31, 2006
  $ 95,310     $ 511,278     $ 19,160     $ 625,748  
Goodwill acquired
          209,928             209,928  
Goodwill related to partnership interests
          345             345  
Other (1)
          (2,685 )           (2,685 )
 
                       
Balance as of June 30, 2007
  $ 95,310     $ 718,866     $ 19,160     $ 833,336  
 
                       
 
(1)   Comprised of purchase price adjustments and the contribution of assets in return for a minority interest in a partially-owned subsidiary.
     In addition to goodwill, we have amortizable intangible assets at June 30, 2007 and December 31, 2006 as follows (in thousands):
                                                 
    As of June 30, 2007     As of December 31, 2006  
    Gross             Net     Gross             Net  
    Carrying     Accumulated     Carrying     Carrying     Accumulated     Carrying  
    Amount     Amortization     Amount     Amount     Amortization     Amount  
Covenants not-to-compete
  $ 14,801     $ (6,476 )   $ 8,325     $ 12,687     $ (6,169 )   $ 6,518  
Non-contractual customer relationships
    9,869       (1,984 )     7,885       9,869       (1,553 )     8,316  
Technology
    1,270       (695 )     575       1,270       (568 )     702  
Trademarks
    582       (156 )     426       569       (127 )     442  
Contracts
    380       (261 )     119       397       (231 )     166  
Client lists
    471       (45 )     426       506       (357 )     149  
 
                                   
Total
  $ 27,373     $ (9,617 )   $ 17,756     $ 25,298     $ (9,005 )   $ 16,293  
 
                                   
     The following table summarizes our aggregate amortization expense related to other intangible assets (in thousands):
                                 
    Three Months Ended     Six Months Ended  
    June 30,     June 30,  
    2007     2006     2007     2006  
Aggregate amortization expense
  $ 1,065     $ 868     $ 2,030     $ 1,728  
 
                       

6


Table of Contents

     The estimated amortization expense related to intangible assets for each of the five succeeding years and thereafter as of June 30, 2007 is as follows (in thousands):
         
Remainder of 2007
  $ 2,193  
2008
    3,924  
2009
    2,771  
2010
    1,749  
2011
    1,143  
Thereafter
    5,976  
 
     
Total
  $ 17,756  
 
     
5. Share-Based Compensation
     During the six months ended June 30, 2007, we granted 351,432 nonvested shares with a weighted-average grant date fair value of $32.75 per share. At June 30, 2007, there was $9.7 million of unrecognized compensation cost related to these nonvested shares that will be recognized over a weighted-average period of 3.5 years. In addition to the unrecognized compensation cost related to our nonvested shares, at June 30, 2007, there was $2.3 million of unrecognized compensation cost related to stock options granted prior to January 1, 2007, that will be recognized over a weighted-average period of 1.3 years.
6. Income Taxes
     The effective tax rate for the six months ended June 30, 2006 includes a tax benefit in the amount of $6.8 million recognized during the first quarter of 2006 due to the outcome of an income tax audit that resulted in a reduction to our estimated tax liabilities.
7. Calculation of Earnings per Common Share
     Basic earnings per common share is calculated by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per common share is calculated by dividing net income by the weighted-average number of common shares outstanding after giving effect to all dilutive potential common shares outstanding during the period. Basic and diluted earnings per common share were calculated as follows (in thousands, except per share amounts):
                                 
    Three Months Ended     Six Months Ended  
    June 30,     June 30,  
    2007     2006     2007     2006  
Net income
  $ 35,847     $ 29,553     $ 64,160     $ 59,212  
 
                       
 
                               
Weighted-average common shares outstanding:
                               
Basic
    83,742       83,118       83,674       82,966  
Effect of dilutive potential common shares:
                               
Stock options and nonvested shares
    1,863       1,720       1,807       1,733  
 
                       
Diluted
    85,605       84,838       85,481       84,699  
 
                       
 
                               
Basic earnings per common share
  $ 0.43     $ 0.36     $ 0.77     $ 0.71  
 
                       
Diluted earnings per common share
  $ 0.42     $ 0.35     $ 0.75     $ 0.70  
 
                       
8. Segment Reporting
     We have four reportable segments: laboratory, animal hospital, medical technology and corporate. These segments are strategic business units that have different services, products and/or functions. The segments are managed separately because each is a distinct and different business venture with unique challenges, risks and rewards. The laboratory segment provides diagnostic laboratory testing services for veterinarians, both associated with our animal hospitals and those independent of us. The animal hospital segment provides veterinary services for

7


Table of Contents

companion animals and sells related retail and pharmaceutical products. The medical technology segment sells digital radiography and ultrasound imaging equipment, related computer hardware, software and ancillary services to the veterinary market. The corporate segment provides general and administrative support services for the other segments.
     The accounting policies of our segments are the same as those described in the summary of significant accounting policies included in our 2006 annual report on Form 10-K. We evaluate the performance of our segments based on gross profit and operating income. For purposes of reviewing the operating performance of our segments, all intercompany sales and purchases are accounted for as if they were transactions with independent third parties at current market prices.

8


Table of Contents

     Below is a summary of certain financial data for each of our segments (in thousands):
                                                 
            Animal     Medical             Intercompany        
    Laboratory     Hospital     Technology     Corporate     Eliminations     Total  
Three Months Ended June 30, 2007
                                               
External revenue
  $ 72,027     $ 218,466     $ 9,812     $     $     $ 300,305  
Intersegment revenue
    7,183             823             (8,006 )      
 
                                   
Total revenue
    79,210       218,466       10,635             (8,006 )     300,305  
Direct costs
    39,244       172,165       6,850             (7,832 )     210,427  
 
                                   
Gross profit
    39,966       46,301       3,785             (174 )     89,878  
Selling, general and administrative expense
    5,046       5,321       2,693       8,983             22,043  
Write-down and loss on sale of assets
    58       322       40                   420  
 
                                   
Operating income (loss)
  $ 34,862     $ 40,658     $ 1,052     $ (8,983 )   $ (174 )   $ 67,415  
 
                                   
 
                                               
Depreciation and amortization
  $ 1,593     $ 4,420     $ 428     $ 460     $ (92 )   $ 6,809  
Capital expenditures
  $ 4,601     $ 9,324     $ 176     $ 1,526     $ (266 )   $ 15,361  
 
                                               
Three Months Ended June 30, 2006
                                               
External revenue
  $ 61,577     $ 186,002     $ 7,571     $     $     $ 255,150  
Intersegment revenue
    5,896             829             (6,725 )      
 
                                   
Total revenue
    67,473       186,002       8,400             (6,725 )     255,150  
Direct costs
    34,949       146,351       5,256             (6,368 )     180,188  
 
                                   
Gross profit
    32,524       39,651       3,144             (357 )     74,962  
Selling, general and administrative expense
    4,349       5,123       2,549       7,463             19,484  
Gain on sale of assets
    (2 )     (83 )                       (85 )
 
                                   
Operating income (loss)
  $ 28,177     $ 34,611     $ 595     $ (7,463 )   $ (357 )   $ 55,563  
 
                                   
 
                                               
Depreciation and amortization
  $ 1,080     $ 3,569     $ 373     $ 444     $ (37 )   $ 5,429  
Capital expenditures
  $ 2,194     $ 4,647     $ 38     $ 500     $ (172 )   $ 7,207  

9


Table of Contents

                                                 
            Animal     Medical             Intercompany        
    Laboratory     Hospital     Technology     Corporate     Eliminations     Total  
Six Months Ended June 30, 2007
                                               
External revenue
  $ 139,269     $ 405,637     $ 20,544     $     $     $ 565,450  
Intersegment revenue
    13,538             1,263             (14,801 )      
 
                                   
Total revenue
    152,807       405,637       21,807             (14,801 )     565,450  
Direct costs
    76,839       323,756       13,711             (14,654 )     399,652  
 
                                   
Gross profit
    75,968       81,881       8,096             (147 )     165,798  
Selling, general and administrative expense
    10,013       10,881       5,628       16,994             43,516  
Write-down and loss on sale of assets
    58       444       40                   542  
 
                                   
Operating income (loss)
  $ 65,897     $ 70,556     $ 2,428     $ (16,994 )   $ (147 )   $ 121,740  
 
                                   
 
                                               
Depreciation and amortization
  $ 2,946     $ 8,290     $ 807     $ 878     $ (181 )   $ 12,740  
Capital expenditures
  $ 7,724     $ 16,280     $ 424     $ 3,136     $ (328 )   $ 27,236  
 
                                               
Six Months Ended June 30, 2006
                                               
External revenue
  $ 117,703     $ 356,525     $ 15,102     $     $     $ 489,330  
Intersegment revenue
    11,307             1,290             (12,597 )      
 
                                   
Total revenue
    129,010       356,525       16,392             (12,597 )     489,330  
Direct costs
    67,936       284,277       10,746             (12,112 )     350,847  
 
                                   
Gross profit
    61,074       72,248       5,646             (485 )     138,483  
Selling, general and administrative expense
    8,443       9,946       5,200       14,780             38,369  
Loss (gain) on sale of assets
    8       (211 )                       (203 )
 
                                   
Operating income (loss)
  $ 52,623     $ 62,513     $ 446     $ (14,780 )   $ (485 )   $ 100,317  
 
                                   
 
                                               
Depreciation and amortization
  $ 2,152     $ 7,097     $ 774     $ 896     $ (68 )   $ 10,851  
Capital expenditures
  $ 2,964     $ 11,377     $ 85     $ 940     $ (299 )   $ 15,067  
 
                                               
At June 30, 2007
                                               
Total assets
  $ 182,718     $ 905,655     $ 47,629     $ 92,160     $ (7,156 )   $ 1,221,006  
 
                                   
 
                                               
At December 31, 2006
                                               
Total assets
  $ 167,363     $ 671,975     $ 53,161     $ 85,533     $ (6,075 )   $ 971,957  
 
                                   
9. Commitments and Contingencies
     We have certain commitments, including operating leases and supply purchase agreements. These items are discussed in detail in our consolidated financial statements and notes thereto included in our 2006 annual report on Form 10-K. We also have contingencies, which are discussed below.
a. Earn-out Payments
     We have contractual arrangements in connection with certain acquisitions, whereby additional cash may be paid to former owners of acquired companies upon attainment of specified financial criteria as set forth in the respective agreements. The amount to be paid cannot be determined until the earn-out periods expire and the attainment of criteria is established. If the specified financial criteria are attained, we will be obligated to pay an additional $813,000.

10


Table of Contents

b. Officers’ Compensation
     Our Chief Executive Officer (“CEO”), Chief Operating Officer (“COO”) and Chief Financial Officer (“CFO”) have entered into employment agreements with our company that provide for base salaries and annual bonuses set by our Compensation Committee of the Board of Directors.
     As of any given date, under their contracts, each officer has the remaining term: five years for the CEO, three years for the COO and two years for the CFO. The contracts have the following additional provisions:
    In the event any of these officers’ employment is terminated due to death or disability, each officer, or their estate, is entitled to receive the remaining base salary during the remaining scheduled term of his employment agreement, the acceleration of the vesting of his options, which options shall remain exercisable for the full term, and the right to continue receiving specified benefits and perquisites.
 
    In the event any of these officers terminate their employment agreements for cause, we terminate any of their employment agreements without cause or a change of control occurs (in which case such employment agreements terminate automatically), each officer is entitled to receive the remaining base salary during the remaining scheduled term of his employment agreement, a bonus based on past bonuses, the acceleration of the vesting of his options, which options shall remain exercisable for the full term, and the right to continue receiving specified benefits and perquisites.
 
    In the event of a change of control, the cash value of all benefits due under their employment contracts as a result of the termination would be immediately payable to the officers. In addition, if any of the amounts payable to these officers under these provisions constitute “excess parachute payments” under the Internal Revenue Code, each officer is entitled to an additional payment to cover the tax consequences associated with the excess parachute payment.
     In addition to the agreements with each of our Chief Officers, we entered into a letter agreement with one of our Senior Vice Presidents whereby in the event his employment is terminated for any reason other than cause, he is entitled to receive an amount equal to one year’s base salary in effect at the date of termination and the right to continue receiving specified benefits and perquisites for a period of one year. Our Senior Vice President’s base salary and annual bonus are set by our Compensation Committee of the Board of Directors.
c. Other Contingencies
     We have certain contingent liabilities resulting from litigation and claims incidental to the ordinary course of our business that we believe will not have a material adverse effect on our future consolidated financial position, results of operations or cash flows.
10. Recent Accounting Pronouncements
     In June 2006, the Financial Accounting Standards Board (“FASB”) issued FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes — an interpretation of FASB Statement No. 109 (“FIN 48”), which clarifies the accounting for uncertainty in tax positions. FIN 48 prescribes recognition thresholds and measurement attributes for the financial statement recognition of income tax positions. In the first quarter of 2007, we adopted FIN 48. We did not have any unrecognized tax benefits at June 30, 2007, and the adoption of FIN 48 did not have a material effect on our condensed, consolidated financial statements.
     In September 2006, the FASB issued Statement of Financial Accounting Standards (“SFAS”) No. 157, Fair Value Measurements (“SFAS No. 157”), which establishes a framework for using and disclosing estimates in accounting for certain assets, liabilities and transactions at fair value. The provisions of SFAS No. 157 will be effective for our company on January 1, 2008. We are currently evaluating the impact of adopting SFAS No. 157 on our consolidated financial statements.
     In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities — Including an amendment of FASB No.115 (“SFAS No. 159”), which permits entities to choose to measure many financial instruments and certain other items at fair value. The provisions of SFAS No. 159 will be effective for our company on January 1, 2008. We are currently evaluating the impact of adopting SFAS No. 159 on our consolidated financial statements.

11


Table of Contents

ITEM 2.   MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
         
    Page
    Number
    13  
 
       
    13  
 
       
    15  
 
       
    21  
 
       
    23  
 
       
    26  
 
       
    26  

12


Table of Contents

Introduction
      The following discussion should be read in conjunction with our condensed, consolidated financial statements provided under Part I, Item I of this quarterly report on Form 10-Q . We have included herein statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We generally identify forward-looking statements in this report using words like “believe,” “intend,” “expect,” “estimate,” “may,” “plan,” “should plan,” “project,” “contemplate,” “anticipate,” “predict,” “potential,” “continue,” or similar expressions. You may find some of these statements below and elsewhere in this report. These forward-looking statements are not historical facts and are inherently uncertain and outside of our control. Any or all of our forward-looking statements in this report may turn out to be wrong. They can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Many factors mentioned in our discussion in this report will be important in determining future results. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially. Factors that may cause our plans, expectations, future financial condition and results to change are described throughout this report and in our annual report on Form 10-K , particularly in “Risk Factors,” Part I, Item 1A of that report.
      The forward-looking information set forth in this quarterly report on Form 10-Q is as of August 7, 2007, and we undertake no duty to update this information. Shareholders and prospective investors can find information filed with the SEC after August 7, 2007 at our website at http://.investor.vcaantech.com or at the SEC’s website at www.sec.gov .
     We are a leading national animal healthcare services company that provides veterinary services and diagnostic testing to support veterinary care and sells diagnostic imaging equipment, other medical technology products and related services to veterinarians. Our four reportable segments are as follows:
    Our laboratory segment operates the largest network of veterinary diagnostic laboratories in the nation. Our laboratories provide sophisticated testing and consulting services used by veterinarians in the detection, diagnosis, evaluation, monitoring, treatment and prevention of diseases and other conditions affecting animals. At June 30, 2007, our laboratory network consisted of 33 laboratories serving all 50 states.
 
    Our animal hospital segment operates the largest network of freestanding, full-service animal hospitals in the nation. Our animal hospitals offer a full range of general medical and surgical services for companion animals. We treat diseases and injuries, offer pharmaceutical and retail products and perform a variety of pet wellness programs, including health examinations, diagnostic testing, routine vaccinations, spaying, neutering and dental care. At June 30, 2007, our animal hospital network consisted of 437 animal hospitals in 38 states.
 
    Our medical technology segment sells digital radiography and ultrasound imaging equipment, related computer hardware, software and ancillary services.
 
    Our corporate segment provides general and administrative support for our other segments.
     The practice of veterinary medicine is subject to seasonal fluctuation. In particular, demand for veterinary services is significantly higher during the warmer months because pets spend a greater amount of time outdoors where they are more likely to be injured and are more susceptible to disease and parasites. In addition, use of veterinary services may be affected by levels of flea infestation, heartworm and ticks, and the number of daylight hours.
Executive Overview
     The three and six months ended June 30, 2007 was marked by continued growth in our laboratory and animal hospital operating segments achieved through a combination of internal growth and acquisitions, including the acquisition of Healthy Pet Corp. (“Healthy Pet”) on June 1, 2007. For the three and six months ended June 30, 2007, our laboratory internal revenue growth was 15.9% and 16.6%, respectively, and our animal hospital same-store revenue growth was 6.6% and 6.1%, respectively. Our medical technology segment also experienced growth through the sale of its digital radiography and ultrasound imaging equipment.

13


Table of Contents

Acquisitions and Facilities
     Our growth strategy includes the acquisition of independent animal hospitals. We currently anticipate that animal hospital acquired revenue for 2007 (exclusive of our acquisition of Healthy Pet discussed below) will range from $55.0 million to $65.0 million. In addition, we also evaluate the acquisition of animal hospital chains, laboratories or related businesses if favorable opportunities are presented. In accordance with that strategy, on June 1, 2007, we acquired Healthy Pet, which operated 44 animal hospitals and a small laboratory that primarily serviced its own animal hospitals. The acquisition of Healthy Pet provided us with the opportunity to expand our animal hospital operations on the East Coast, particularly in Massachusetts, Connecticut, Virginia and Georgia. The following table summarizes the changes in the number of facilities operated by our laboratory and animal hospital segments during the six months ended June 30, 2007:
         
Laboratories:
       
Beginning of period
    33  
Acquisitions
    1  
Acquisitions relocated into our existing laboratories
    (1 )
 
     
End of period
    33  
 
     
 
       
Animal hospitals :
       
Beginning of period
    379  
Acquisitions, excluding Healthy Pet
    24  
Healthy Pet
    44  
Acquisitions relocated into our existing animal hospitals
    (7 )
Closed
    (3 )
 
     
End of period
    437  
 
     
Financing Transaction
     On June 1, 2007, we amended our senior credit facility to allow for additional senior term notes in the amount of $160.0 million. The funds borrowed from the additional senior term notes were primarily used to fund the acquisition of Healthy Pet on June 1, 2007. The terms, including the interest rate, of these additional senior term notes are the same as the senior term notes existing prior to the amendment. Principal payments on the additional senior term notes are due quarterly in the amount of $400,000 and a final payment in the amount of $153.6 million is due on May 16, 2011.

14


Table of Contents

Results of Operations
The following table sets forth components of our condensed, consolidated income statements expressed as a percentage of revenue:
                                 
    Three Months Ended     Six Months Ended  
    June 30,     June 30,  
    2007     2006     2007     2006  
Revenue:
                               
Laboratory
    26.4 %     26.4 %     27.0 %     26.4 %
Animal hospital
    72.7       72.9       71.7       72.9  
Medical technology
    3.5       3.3       3.9       3.3  
Intercompany
    (2.6 )     (2.6 )     (2.6 )     (2.6 )
 
                       
Total revenue
    100.0       100.0       100.0       100.0  
Direct costs
    70.1       70.6       70.7       71.7  
 
                       
 
Gross profit
    29.9       29.4       29.3       28.3  
Selling, general and administrative expense
    7.3       7.6       7.7       7.8  
Write-down and loss on sale of assets
    0.2             0.1        
 
                       
Operating income
    22.4       21.8       21.5       20.5  
Interest expense, net
    2.2       2.3       2.3       2.5  
Other expense
    0.1                    
 
                       
Income before minority interest and provision for income taxes
    20.1       19.5       19.2       18.0  
Minority interest in income of subsidiaries
    0.3       0.4       0.3       0.3  
 
                       
Income before provision for income taxes
    19.8       19.1       18.9       17.7  
Provision for income taxes
    7.9       7.5       7.6       5.6  
 
                       
Net income
    11.9 %     11.6 %     11.3 %     12.1 %
 
                       
Revenue
     The following table summarizes our revenue (in thousands, except percentages):
                                                                                 
    Three Months Ended June 30,     Six Months Ended June 30,  
    2007     2006             2007     2006        
            % of             % of     %             % of             % of     %  
    $     Total     $     Total     Change     $     Total     $     Total     Change  
Laboratory
  $ 79,210       26.4 %   $ 67,473       26.4 %     17.4 %   $ 152,807       27.0 %   $ 129,010       26.4 %     18.4 %
Animal hospital
    218,466       72.7 %     186,002       72.9 %     17.5 %     405,637       71.7 %     356,525       72.9 %     13.8 %
Medical technology
    10,635       3.5 %     8,400       3.3 %     26.6 %     21,807       3.9 %     16,392       3.3 %     33.0 %
Intercompany
    (8,006 )     (2.6 )%     (6,725 )     (2.6 )%     19.0 %     (14,801 )     (2.6 )%     (12,597 )     (2.6 )%     17.5 %
 
                                                                       
Total revenue
  $ 300,305       100.0 %   $ 255,150       100.0 %     17.7 %   $ 565,450       100.0 %   $ 489,330       100.0 %     15.6 %
 
                                                                       

15


Table of Contents

Laboratory Revenue
     Laboratory revenue increased $11.7 million for the three months ended June 30, 2007 and increased $23.8 million for the six months ended June 30, 2007 as compared to the same periods in the prior year. The components of the increase in laboratory revenue are detailed below (in thousands, except percentages and average price per requisition):
                                                 
    Three Months Ended June 30,     Six Months Ended June 30,  
    2007     2006     % Change     2007     2006     % Change  
Laboratory Revenue:
                                               
Internal growth:
                                               
Number of requisitions (1)
    3,441       3,000       14.7 %     6,511       5,624       15.8 %
Average revenue per requisition (2)
  $ 22.72     $ 22.49       1.0 %   $ 23.10     $ 22.94       0.7 %
 
                                       
Total internal revenue (1)
  $ 78,186     $ 67,473       15.9 %   $ 150,403     $ 129,010       16.6 %
Acquired revenue (3)
    1,024                     2,404                
 
                                       
Total
  $ 79,210     $ 67,473       17.4 %   $ 152,807     $ 129,010       18.4 %
 
                                       
 
(1)   Internal revenue and requisitions were calculated using laboratory operating results, adjusted to exclude the operating results of acquired laboratories for the comparable periods that we did not own those laboratories in the prior year, and adjusted for the impact resulting from any differences in the number of billing days in the comparable periods.
 
(2)   Computed by dividing internal revenue by the number of requisitions.
 
(3)   Acquired revenue represents revenue recognized from our acquired laboratories for the comparable current year period that we did not own them in the prior year.
     The increase in requisitions from internal growth is the result of a continued trend in veterinary medicine to focus on the importance of laboratory diagnostic testing in the diagnosis, early detection and treatment of diseases, and the migration of certain tests to outside laboratories that have historically been performed in veterinary hospitals. This trend is driven by an increase in the number of specialists in the veterinary industry relying on diagnostic testing, the increased focus on diagnostic testing in veterinary schools and general increased awareness through ongoing marketing and continuing education programs provided by us, pharmaceutical companies and other service providers in the industry. Also contributing to the increase in the number of requisitions was the pet food recall that occurred in March 2007.
     Competition in the veterinary laboratory services industry is intense. We derive our laboratory revenue from services provided to over 15,000 independently owned animal hospitals and shifts in the purchasing habits of any individual animal hospital or small group of animal hospitals is not material to our laboratory revenues. Other companies are developing networks of animal hospitals and shifts in the purchasing habits of these networks have the potential of a greater impact on our laboratory revenues. No single customer represented more than 10% of our laboratory revenues during the periods presented.
     The change in the average revenue per requisition is attributable to changes in the mix, including those tests historically performed at veterinary hospitals, type and number of tests performed per requisition and price increases. The price increases for most tests ranged from 3% to 5% in February 2007 and February 2006.

16


Table of Contents

Animal Hospital Revenue
     Animal hospital revenue increased $32.5 million for the three months ended June 30, 2007 and increased $49.1 million for the six months ended June 30, 2007 as compared to the same periods in the prior year. The components of the increase are summarized in the following table (in thousands, except percentages and average price per order):
                                                 
    Three Months Ended June 30,     Six Months Ended June 30,  
    2007     2006     % Change     2007     2006     % Change  
Animal Hospital Revenue:
                                               
Same-store facilities:
                                               
Orders (1)(2)
    1,381       1,375       0.5 %     2,598       2,589       0.3 %
Average revenue per order (3)
  $ 141.75     $ 133.61       6.1 %   $ 141.25     $ 133.57       5.7 %
 
                                       
Same-store revenue (1)
  $ 195,827     $ 183,712       6.6 %   $ 366,949     $ 345,869       6.1 %
Net acquired revenue (4)
    22,639       2,290               38,688       10,656          
 
                                       
Total
  $ 218,466     $ 186,002       17.5 %   $ 405,637     $ 356,525       13.8 %
 
                                       
 
(1)   Same-store revenue and orders were calculated using animal hospital operating results, adjusted to exclude the operating results for newly acquired animal hospitals that we did not own as of the beginning of the comparable period in the prior year and adjusted for the impact resulting from any differences in the number of business days in the comparable periods. Same-store revenue also includes revenue generated by customers referred from our relocated or combined animal hospitals, including those merged upon acquisition.
 
(2)   The change in orders may not calculate exactly due to rounding.
 
(3)   Computed by dividing same-store revenue by same-store orders. The average revenue per order may not calculate exactly due to rounding.
 
(4)   Net acquired revenue represents the revenue from those animal hospitals acquired, net of revenue from those animal hospitals sold or closed, on or after the beginning of the comparable period, which was April 1, 2006 for the three-month analysis, and January 1, 2006 for the six-month analysis. Fluctuations in net acquired revenue occur due to the volume, size and timing of acquisitions and dispositions during the periods from this date through the end of the applicable period.
     Our business strategy is to place a greater emphasis on comprehensive wellness visits and advanced medical procedures, which typically generate higher-priced orders. Over the last few years, some pet-related products traditionally sold in our animal hospitals are now widely available in retail stores and other distribution channels. In addition, there has been a decline in the number of vaccinations as some recent professional literature and research has suggested that vaccinations can be given to pets less frequently. These trends have resulted in a decrease in lower-priced orders and an increase in higher-priced orders. Although we experienced an increase in the number of orders for the three and six months ended June 30, 2007, we may experience a decrease in the number of orders in future periods for the reasons discussed above.
     Price increases, which approximated 5% to 6% on most services at most of our hospitals in February 2007 and February 2006, also contributed to the increase in the average revenue per order. Prices are reviewed on an annual basis for each hospital and adjustments are made based on market considerations, demographics and our costs.
Medical Technology Revenue
     Medical technology revenue increased $2.2 million for the three months ended June 30, 2007 and increased $5.4 million for the six months ended June 30, 2007 as compared to the comparable periods in the prior year. This increase was primarily attributable to revenue recognized for current and historical sales of our digital radiography and ultrasound imaging equipment. We recognize revenue on deferred sales ratably over a period ranging from one to five years. These deferred transactions are further discussed below in Critical Accounting Policies . At June 30, 2007, we had deferred revenue of $10.5 million.
Intercompany Revenue
     Laboratory revenue for the three and six months ended June 30, 2007 included intercompany revenue of $7.2 million and $13.5 million, respectively, that was generated by providing laboratory services to our animal hospitals. Medical technology revenue for the three and six months ended June 30, 2007 included intercompany revenue of

17


Table of Contents

$823,000 and $1.3 million, respectively, that was generated by providing products and services to our animal hospitals and laboratories. For purposes of reviewing the operating performance of our business segments, all intercompany transactions are accounted for as if the transaction was with an independent third party at current market prices. For financial reporting purposes, intercompany transactions are eliminated as part of our consolidation.
Gross Profit
     The following table summarizes our gross profit and our gross profit as a percentage of applicable revenue, or gross margin (in thousands, except percentages):
                                                                                 
    Three Months Ended June 30,     Six Months Ended June 30,  
    2007     2006             2007     2006        
            Gross             Gross     %             Gross             Gross     %  
    $     Margin     $     Margin     Change     $     Margin     $     Margin     Change  
Laboratory
  $ 39,966       50.5 %   $ 32,524       48.2 %     22.9 %   $ 75,968       49.7 %   $ 61,074       47.3 %     24.4 %
Animal hospital
    46,301       21.2 %     39,651       21.3 %     16.8 %     81,881       20.2 %     72,248       20.3 %     13.3 %
Medical technology
    3,785       35.6 %     3,144       37.4 %     20.4 %     8,096       37.1 %     5,646       34.4 %     43.4 %
Intercompany
    (174 )             (357 )                     (147 )             (485 )                
 
                                                                       
Total gross profit
  $ 89,878       29.9 %   $ 74,962       29.4 %     19.9 %   $ 165,798       29.3 %   $ 138,483       28.3 %     19.7 %
 
                                                                       
Laboratory Gross Profit
     Laboratory gross profit is calculated as laboratory revenue less laboratory direct costs. Laboratory direct costs are comprised of all costs of laboratory services, including but not limited to, salaries of veterinarians, specialists, technicians and other laboratory-based personnel, transportation and delivery costs, supply costs, facilities rent, occupancy costs, depreciation and amortization.
     The increase in laboratory gross margin was primarily attributable to increases in laboratory revenue combined with operating leverage associated with our laboratory business. Our operating leverage comes from the incremental margins we realize on additional tests ordered by the same client, as well as when more comprehensive tests are ordered. We are able to benefit from these incremental margins due to the relative fixed cost nature of our laboratory business.
Animal Hospital Gross Profit
     Animal hospital gross profit is calculated as animal hospital revenue less animal hospital direct costs. Animal hospital direct costs are comprised of all costs of services and products at the animal hospitals, including, but not limited to, salaries of veterinarians, technicians and all other animal hospital-based personnel, facilities rent, occupancy costs, supply costs, depreciation and amortization, certain marketing and promotional expense and costs of goods sold associated with the retail sales of pet food and pet supplies.
     During the three and six months ended June 30, 2007, our animal hospital same-store gross margin improved as compared to the comparable periods in the prior year due to improvements in revenue and operating leverage. Our animal hospital same-store gross margin was 21.6% and 21.4% for the three months ended June 30, 2007 and 2006, respectively, and 20.5% and 20.4 % for the six months ended June 30, 2007 and 2006, respectively. Due primarily to our recent animal hospital acquisitions, our animal hospital consolidated gross margin for the three and six months ended June 30, 2007 declined slightly from the comparable prior year period.
Medical Technology Gross Profit
     Medical technology gross profit is calculated as medical technology revenue less medical technology direct costs. Medical technology direct costs are comprised of all product and service costs, including, but not limited to, all costs of equipment, related products and services, salaries of technicians, support personnel, trainers, consultants and other non-administrative personnel, depreciation and amortization, and supply costs.

18


Table of Contents

     During the three months ended June 30, 2007, our medical technology gross margin declined as compared to the comparable period in the prior year primarily due to an increase in material cost as a percentage of revenue related to the sale of our digital radiography imaging equipment.
     During the six months ended June 30, 2007, our medical technology gross margin increased as compared to the comparable period in the prior year primarily due to inventory charges recognized in 2006 that were partially offset by an increase in material cost as a percentage of revenue related to the sale of our digital radiography imaging equipment.
     We defer the revenue and related costs of certain transactions as discussed below in Critical Accounting Policies . For these transactions, the revenue and related costs are recognized ratably over a period ranging from one to five years. At June 30, 2007, we had deferred revenue and costs of $10.5 million and $4.7 million, respectively.
Selling, General and Administrative Expense
     The following table summarizes our selling, general and administrative expense (“SG&A”), and our expense as a percentage of applicable revenue (in thousands, except percentages):
                                                                                 
    Three Months Ended June 30,     Six Months Ended June 30,  
    2007     2006             2007     2006        
            % of             % of     %             % of             % of     %  
    $     Revenue     $     Revenue     Change     $     Revenue     $     Revenue     Change  
Laboratory
  $ 5,046       6.4 %   $ 4,349       6.4 %     16.0 %   $ 10,013       6.6 %   $ 8,443       6.5 %     18.6 %
Animal hospital
    5,321       2.4 %     5,123       2.8 %     3.9 %     10,881       2.7 %     9,946       2.8 %     9.4 %
Medical technology
    2,693       25.3 %     2,549       30.3 %     5.6 %     5,628       25.8 %     5,200       31.7 %     8.2 %
Corporate
    8,983       3.0 %     7,463       2.9 %     20.4 %     16,994       3.0 %     14,780       3.0 %     15.0 %
 
                                                                       
Total SG&A
  $ 22,043       7.3 %   $ 19,484       7.6 %     13.1 %   $ 43,516       7.7 %   $ 38,369       7.8 %     13.4 %
 
                                                                       
Laboratory SG&A
     Laboratory SG&A consists primarily of salaries of sales, administrative and accounting personnel, selling, marketing and promotional expense.
     The increase in laboratory SG&A was primarily attributable to an increase in commissions. Marketing costs and administrative support also contributed to the increase in laboratory SG&A.
Animal Hospital SG&A
     Animal hospital SG&A consists primarily of salaries of field management, certain administrative and accounting personnel, recruiting and certain marketing expense.
     The increase in animal hospital SG&A was primarily attributable to expanding the animal hospital administrative operations to absorb our recent acquisitions.
Medical Technology SG&A
     Medical technology SG&A consists primarily of salaries of sales, administrative and accounting personnel, selling, marketing and promotional expense and research and development costs.
     The increase in medical technology SG&A was primarily attributable to marketing costs and administrative support.

19


Table of Contents

Corporate SG&A
     Corporate SG&A consists of administrative expense at our headquarters, including the salaries of corporate officers, administrative and accounting personnel, rent, accounting, finance, legal and other professional expense and occupancy costs as well as corporate depreciation.
     The increase in corporate SG&A was primarily attributable to expanding the corporate operations to absorb our recent acquisitions and integration costs of $675,000 relating to the acquisition of Healthy Pet.
Write-down and Loss (Gain) on Sale of Assets
     During the six months ended June 30, 2007 and 2006, we wrote-down and sold certain assets, including real estate, for a net loss of $542,000 and a gain of $203,000, respectively.
Interest Expense, Net
     The following table summarizes our interest expense, net of interest income (in thousands):
                                 
    Three Months Ended     Six Months Ended  
    June 30,     June 30,  
    2007     2006     2007     2006  
Interest expense:
                               
Senior term notes
  $ 7,369     $ 6,504     $ 13,774     $ 12,918  
Interest rate hedging agreements
    (529 )     (370 )     (1,018 )     (571 )
Capital leases and other
    349       197       699       609  
Amortization of debt costs
    76       94       137       227  
 
                       
 
    7,265       6,425       13,592       13,183  
Interest income
    594       498       1,148       944  
 
                       
Total interest expense, net of interest income
  $ 6,671     $ 5,927     $ 12,444     $ 12,239  
 
                       
     The increase in interest expense was primarily attributable to additional senior term notes in the amount of $160.0 million borrowed under our senior credit facility on June 1, 2007 and increases in LIBOR. These factors were partially offset by principal repayments, including $60.0 million of voluntary debt repayments throughout 2006.
Provision for Income Taxes
     Our effective tax rate for the three months ended June 30, 2007 and 2006 was 39.8% and 39.4%, respectively, and our effective rate for the six months ended June 30, 2007 and 2006 was 40.1% and 31.5%, respectively. The effective tax rate for the six months ended June 30, 2006 includes a tax benefit in the amount of $6.8 million recognized during the first quarter of 2006 due to the outcome of an income tax audit that resulted in a reduction to our estimated tax liabilities.

20


Table of Contents

Liquidity and Capital Resources
     The following table summarizes our cash flows (in thousands):
                 
    Six Months Ended  
    June 30,  
    2007     2006  
Cash provided by (used in):
               
Operating activities
  $ 94,193     $ 64,141  
Investing activities
    (237,212 )     (46,562 )
Financing activities
    160,022       (55,266 )
 
           
Increase (decrease) in cash and cash equivalents
    17,003       (37,687 )
Cash and cash equivalents at beginning of year
    45,104       58,488  
 
           
Cash and cash equivalents at end of period
  $ 62,107     $ 20,801  
 
           
Cash Flows from Operating Activities
     Net cash provided by operating activities increased $30.1 million in the six months ended June 30, 2007 as compared to the same period in the prior year primarily due to improved operating performance, acquisitions and changes in working capital, which was partially offset by an increase in taxes paid of $1.7 million.
     Borrowings under our senior credit facility bear interest based on a variable-rate component plus a margin of 1.50%. Significant increases in interest rates may materially impact our operating cash flows.
Cash Flows from Investing Activities
     Our growth strategy includes the acquisition of independent animal hospitals. We currently anticipate that we will spend $55.0 million to $65.0 million in 2007 on the acquisition of animal hospitals (exclusive of our acquisition of Healthy Pet discussed below). For the six months ended June 30, 2007, we spent $48.2 million related to the acquisition of independent animal hospitals. In addition, we also evaluate the acquisition of animal hospital chains, laboratories or related businesses if favorable opportunities are presented. In accordance with that strategy, we acquired Healthy Pet, which operated 44 animal hospitals and a small laboratory that primarily serviced its own animal hospitals, on June 1, 2007. In connection with the acquisition of Healthy Pet, we paid cash of $154.4 million. We intend to primarily use cash in our acquisitions but, depending on the timing and amount of our acquisitions, we may use stock or debt.
     Our investing activities include expenditures for property and equipment additions and we expect to spend approximately $40.0 million to $45.0 million in 2007 for such expenditures (exclusive of real estate acquired in connection with business acquisitions). For the six months ended June 30, 2007, we spent $27.2 million on property and equipment additions. In addition, due to favorable opportunities presented, we also purchased real estate in connection with certain animal hospital acquisitions in the amount of $8.0 million during the six months ended June 30, 2007.
Cash Flows from Financing Activities
     Net cash provided by our financing activities for the six months ended June 30, 2007 included $160.0 million of borrowings under our senior credit facility in the form of additional senior term notes. These borrowings were primarily used to fund the acquisition of Healthy Pet on June 1, 2007. Net cash used in our financing activities for the six months ended June 30, 2006 consisted primarily of cash used to prepay a portion of our senior term notes in the amount of $60.0 million.

21


Table of Contents

Future Contractual Cash Requirements
     The following table sets forth our scheduled principal, interest and other contractual cash obligations for each of the years indicated (in thousands):
                                                         
    Total     2007 (1)     2008     2009     2010     2011     Thereafter  
Long-term debt
  $ 533,014     $ 3,285     $ 6,106     $ 5,828     $ 5,855     $ 511,940     $  
Capital lease obligations
    15,198       639       1,216       1,243       1,361       1,402       9,337  
Operating leases
    567,277       18,284       37,121       36,774       34,757       34,497       405,844  
Fixed cash interest expense
    6,155       672       1,421       1,127       790       523       1,622  
Variable cash interest expense (2)
    132,414       17,902       33,606       33,344       34,344       13,218        
Swap agreements (2)
    376       (651 )     435       592                    
Purchase obligations
    44,957       12,178       8,134       8,899       9,744       6,002        
Other long-term liabilities (3)
    46,637             65       65       65             46,442  
Earn-out payments (4)
    813       213       300       300                    
 
                                         
 
  $ 1,346,841     $ 52,522     $ 88,404     $ 88,172     $ 86,916     $ 567,582     $ 463,245  
 
                                         
 
(1)   Consists of the period from July 1, 2007 through December 31, 2007.
 
(2)   We have variable-rate debt. The interest payments on our variable-rate debt are based on a variable-rate component plus a margin of 1.50%. For purposes of this computation, we have assumed that the interest rate on our variable-rate debt (including the margin of 1.50%) will be 6.8%, 6.4%, 6.4%, 6.7%, and 6.9% for years 2007 through 2011, respectively. These estimates are based on interest rate projections used to price our interest rate swap agreements. Our consolidated financial statements included in our 2006 annual report on Form 10-K discuss these variable-rate notes in more detail.
 
(3)   Includes deferred income taxes of $44.7 million.
 
(4)   Represents contractual arrangements whereby additional cash may be paid to former owners of acquired businesses upon attainment of specified performance targets.
     We anticipate that our cash on-hand, net cash provided by operations and, if needed, our revolving credit facility, will provide sufficient cash resources to fund our operations for more than the next 12 months. If we consummate one or more significant acquisitions during this period we may need to seek additional debt or equity financing.
Debt Related Covenants
     Our senior credit facility contains certain financial covenants pertaining to fixed charge coverage and leverage ratios. In addition, the senior credit facility has restrictions pertaining to capital expenditures, acquisitions and the payment of cash dividends. As of June 30, 2007, we were in compliance with these covenants, including the two covenant ratios, the fixed charge coverage ratio and the leverage ratio.
     The senior credit facility defines the fixed charge coverage ratio as that ratio that is calculated on a last 12-month basis by dividing pro forma earnings before interest, taxes, depreciation and amortization, as defined by the senior credit facility, by fixed charges. Pro forma earnings before interest, taxes, depreciation and amortization include 12 months of operating results for businesses acquired during the period. Fixed charges are defined as cash interest expense, scheduled principal payments on debt obligations, capital expenditures, and provision for income taxes. At June 30, 2007, we had a fixed charge coverage ratio of 1.51 to 1.00, which was in compliance with the required ratio of no less than 1.20 to 1.00.
     The senior credit facility defines the leverage ratio as that ratio which is calculated as total debt divided by pro forma earnings before interest, taxes, depreciation and amortization, as defined by the senior credit facility. At June 30, 2007, we had a leverage ratio of 2.14 to 1.00, which was in compliance with the required ratio of no more than 3.25 to 1.00.

22


Table of Contents

Interest Rate Swap Agreements
     We have interest rate swap agreements whereby we pay counterparties amounts based on fixed interest rates and set notional principal amounts in exchange for the receipt of payments from the counterparties based on London Interbank Offer Rates (“LIBOR”) and the same set notional principal amounts. We entered into these interest rate swap agreements to hedge against the risk of increasing interest rates. The contracts effectively convert a certain amount of our variable-rate debt under our senior credit facility to fixed-rate debt for purposes of controlling cash paid for interest. That amount is equal to the notional principal amount of the interest rate swap agreements, and the fixed-rate conversion period is equal to the terms of the contract. The impact of these interest rate swap agreements has been factored into our future contractual cash requirements table above. All of our interest rate swap agreements at June 30, 2007 qualify for hedge accounting and are summarized as follows:
                     
Fixed interest rate
  4.07%   3.98%   5.51%   4.95%   5.34%
Notional amount (in millions)
  $50.0   $50.0   $50.0   $75.0   $100.0
Effective date
  5/26/2005   6/2/2005   6/20/2006   4/30/2007   6/11/2007
Expiration date
  5/26/2008   5/31/2008   6/30/2009   4/30/2009   12/31/2009
Counterparties
  Goldman Sachs   Wells Fargo   Goldman Sachs   Wells Fargo   Goldman Sachs
     In the future, we may enter into additional interest rate strategies. However, we have not yet determined what those strategies will be or their possible impact.
Description of Indebtedness
Senior Credit Facility
     At June 30, 2007, we had $530.4 million principal amount outstanding under our senior term notes and no borrowings outstanding under our revolving credit facility.
     We pay interest on our senior term notes and our revolving credit facility based on the interest rate offered to our administrative agent on LIBOR plus a margin of 1.50% per annum.
     The senior term notes mature in May 2011 and the revolving credit facility matures in May 2010.
Other Debt
     At June 30, 2007, we had seller notes secured by assets of certain animal hospitals, unsecured debt and capital leases that totaled $17.8 million.
Critical Accounting Policies
     We believe that the application of the following accounting policies, which are important to our financial position and results of operations, requires significant judgments and estimates on the part of management. For a summary of all our accounting policies, including the accounting policies discussed below, see our consolidated financial statements included in our 2006 annual report on Form 10-K.
Revenue
Laboratory and Animal Hospital Revenue
     We recognize revenue when persuasive evidence of a sales arrangement exists, delivery of goods has occurred or services have been rendered, the sales price or fee is fixed or determinable and collectibility is reasonably assured.
Medical Technology Revenue
     Our medical technology segment generates a majority of its revenue from the sale of digital radiography imaging equipment and ultrasound imaging equipment. We also generate revenue from: (i) licensing software; (ii) providing technical support and product updates related to our software, otherwise known as maintenance; (iii) providing professional services related to our equipment and software, including installations, on-site training,

23


Table of Contents

education services and extended warranty programs; and (iv) providing mobile imaging services. We frequently sell equipment and license our software in multiple element arrangements in which the customer may choose a combination of our products and services.
     The accounting for the sale of equipment is substantially governed by the requirements of Staff Accounting Bulletin (“SAB”) No. 104, Revenue Recognition (“SAB No. 104”), and the sale of software licenses and related items is governed by Statement of Position (“SOP”) No. 97-2, Software Revenue Recognition (“SOP No. 97-2”), as amended. The determination of the amount of software license, maintenance and professional service revenue to be recognized in each accounting period requires us to exercise judgment and use estimates. In determining whether or not to recognize revenue, we evaluate each of these criteria:
    Evidence of an arrangement : We consider a non-cancelable agreement signed by the customer and us to be evidence of an arrangement.
 
    Delivery : We consider delivery to have occurred when the ultrasound imaging equipment is delivered. We consider delivery to have occurred when the digital radiography imaging equipment is delivered or accepted by the customer if installation is required. We consider delivery to have occurred with respect to professional services when those services are provided or on a straight-line basis over the service contract term, based on the nature of the service or the terms of the contract.
 
    Fixed or determinable fee : We assess whether fees are fixed or determinable at the time of sale and recognize revenue if all other revenue recognition requirements are met. We generally consider payments that are due within six months to be fixed or determinable based upon our successful collection history. We only consider fees to be fixed or determinable if they are not subject to refund or adjustment.
 
    Collection is deemed probable : We conduct a credit review for all significant transactions at the time of the arrangement to determine the credit worthiness of the customer. Collection is deemed probable if we expect that the customer will be able to pay amounts under the arrangement as payments become due. If we determine that collection is not probable, we defer the revenue and recognize the revenue upon cash collection.
     Under the residual method prescribed by SOP No. 98-9, Modification of SOP No. 97-2, Software Revenue Recognition, With Respect to Certain Transactions (“SOP No. 98-9”), in multiple element arrangements involving software that is more than incidental to the products and services as a whole, revenue is recognized when vendor-specific objective evidence (“VSOE”) of fair value exists for all of the undelivered elements in the arrangement (i.e., maintenance and professional services), but does not exist for one or more of the delivered elements in the arrangement (i.e., the equipment, computer hardware or the software product). VSOE of fair value is based on 1) the price we charge for those products and services when sold on a stand-alone basis independent of other products and services or 2) the contractual renewal rates for the post-contract customer support (“PCS”) services that we provide when we sell multiple products and services in a single transaction. Under the residual method, the fair value of the undelivered elements is deferred and recognized as revenue upon delivery, provided that other revenue recognition criteria are met. If evidence of the fair value of one or more undelivered elements does not exist, the revenue for the entire transaction, including revenue related to the delivered elements, is deferred and recognized, based on the facts and circumstances, either: 1) on a straight-line basis over the life of the PCS period if this is the only undelivered element, or 2) when the last undelivered element is delivered. Each transaction requires careful analysis to determine whether all of the individual elements in the transaction have been identified, that fair value exists for each element and that the transaction is accounted for correctly.
Digital Radiography Imaging Equipment
     We sell our digital radiography imaging equipment with multiple elements, including hardware, software, licenses and/or services. We have determined that the software included in these sales arrangements is more than incidental to the products and services as a whole. As a result, we account for digital radiography imaging equipment sales under SOP No. 97-2, as amended.

24


Table of Contents

     For those sales arrangements where we have determined VSOE of fair value for all undelivered elements, we recognize the residual revenue for the delivered elements at the time of delivery or installation and customer acceptance.
     Generally, at the time of delivery and installation of equipment the only undelivered item is the PCS. This obligation is contractually defined in both terms of scope and period. When we have established VSOE of fair value for the PCS, we recognize the revenue for these services on a straight-line basis over the period of support and recognize revenue for the delivered elements under the residual method. When we have not established VSOE of fair value for the PCS, we defer all revenue, including revenue for the delivered elements, recognizing it on a straight-line basis over the period of support.
Ultrasound Imaging Equipment
     We sell our ultrasound imaging equipment on a stand-alone basis and with multiple elements, including hardware, software, licenses and/or services. We account for the sale of ultrasound imaging equipment on a stand-alone basis under the requirements of SAB No. 104, and recognize revenue upon delivery. We account for the sale of ultrasound imaging equipment with related computer hardware and software by bifurcating the transaction into separate elements. We account for the ultrasound imaging equipment under the requirements of SAB No. 104, as the software is not deemed to be essential to the functionality of the equipment, and account for the computer hardware and software under the requirements of SOP No. 97-2, as amended. For those sales of our ultrasound imaging equipment that include computer hardware and software, we recognize revenue on the ultrasound imaging equipment, computer hardware and software upon delivery, which occurs simultaneously.
Digital Radiography And Ultrasound Imaging Equipment Sold Together
     In certain transactions, we sell our ultrasound imaging equipment and related services together with our digital radiography imaging equipment and related services. In these transactions, we allocate total invoice dollars to each element using a relative fair value basis. Each element is then accounted for pursuant to either SAB No. 104 or SOP No. 97-2, as applicable.
Other Services
     We recognize revenue on mobile imaging, consulting and education services at the time the services have been rendered. We also generate revenue from extended service agreements related to our digital radiography imaging and ultrasound imaging equipment. These extended service agreements include technical support, product updates for software and extended warranty coverage. The revenue for these extended service agreements is recognized on a straight-line basis over the term of the agreement.
Goodwill Impairment
     Our goodwill represents the excess of the cost of an acquired entity over the net of the fair value of identifiable assets acquired and liabilities assumed. The total amount of our goodwill at June 30, 2007 was $833.3 million, consisting of $95.3 million for our laboratory segment, $718.8 million for our animal hospital segment and $19.2 million for our medical technology segment.
     Annually, or sooner if circumstances indicate impairment may exist, we test our goodwill for impairment by comparing the fair market values of our laboratory, animal hospital and medical technology reporting units to their respective net book values. At December 31, 2006, the estimated fair market value of each of our reporting units exceeded their respective net book value, resulting in a conclusion that our goodwill was fairly stated.
Income Taxes
     We account for income taxes under Statement of Financial Accounting Standards (“SFAS”) No. 109, Accounting for Income Taxes (“SFAS No. 109”). In accordance with SFAS No. 109, we record deferred tax assets and deferred tax liabilities, which represent taxes to be recovered or settled in the future. We adjust our deferred tax assets and deferred tax liabilities to reflect changes in tax rates or other statutory tax provisions. Changes in tax rates or other statutory provisions are recognized in the period the change occurs.

25


Table of Contents

     We make judgments in assessing our ability to realize future benefits from our deferred tax assets, which include operating and capital loss carryforwards. As such, we have a valuation allowance to reduce our deferred tax assets for the portion we believe will not be realized.
     In the first quarter of 2007, we adopted Financial Accounting Standards Board (“FASB”) Interpretation No. 48, Accounting for Uncertainty in Income Taxes — an interpretation of FASB Statement No. 109 (“FIN 48”). FIN 48 prescribes recognition thresholds and measurement attributes for the financial statement recognition of income tax positions. We did not have any unrecognized tax benefits at June 30, 2007, and the adoption of FIN 48 did not have a material effect on our condensed, consolidated financial statements.
Recent Accounting Pronouncements
     In June 2006, the FASB issued FIN 48, which clarifies the accounting for uncertainty in tax positions. FIN 48 prescribes recognition thresholds and measurement attributes for the financial statement recognition of income tax positions. In the first quarter of 2007, we adopted FIN 48. We did not have any unrecognized tax benefits at June 30, 2007, and the adoption of FIN 48 did not have a material effect on our condensed, consolidated financial statements.
     In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements (“SFAS No. 157”), which establishes a framework for using and disclosing estimates in accounting for certain assets, liabilities and transactions at fair value. The provisions of SFAS No. 157 will be effective for our company on January 1, 2008. We are currently evaluating the impact of adopting SFAS No. 157 on our consolidated financial statements.
     In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities — Including an amendment of FASB No.115 (“SFAS No. 159”), which permits entities to choose to measure many financial instruments and certain other items at fair value. The provisions of SFAS No. 159 will be effective for our company on January 1, 2008. We are currently evaluating the impact of adopting SFAS No. 159 on our consolidated financial statements.
Forward-Looking Statements
     This quarterly report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties, as well as assumptions that, if they materialize or prove incorrect, could cause our results and the results of our consolidated subsidiaries to differ materially from those expressed or implied by these forward-looking statements. We generally identify forward-looking statements in this report using words like “believe,” “intend,” “expect,” “estimate,” “may,” “plan,” “should plan,” “project,” “contemplate,” “anticipate,” “predict,” “potential,” “continue,” or similar expressions. You may find some of these statements in this report. These forward-looking statements are not historical facts and are inherently uncertain and outside of our control. Any or all of our forward-looking statements in this report may turn out to be wrong. They can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Many factors mentioned in our discussion in this report will be important in determining future results. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially. Factors that may cause our plans, expectations, future financial condition and results to change are described throughout this report and in our annual report on Form 10-K, particularly in Risk Factors , Part I, Item 1A of that report.

26


Table of Contents

ITEM 3.   QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
     At June 30, 2007, we had borrowings of $530.4 million under our senior credit facility with fluctuating interest rates based on market benchmarks such as LIBOR. For our variable-rate debt, changes in interest rates generally do not affect the fair market value, but do impact earnings and cash flow. To reduce the risk of increasing interest rates, we entered into $325.0 million of interest rate swap agreements. Currently, we are engaged in the following interest rate swap agreements:
                     
Fixed interest rate
  4.07%   3.98%   5.51%   4.95%   5.34%
Notional amount (in millions)
  $50.0   $50.0   $50.0   $75.0   $100.0
Effective date
  5/26/2005   6/2/2005   6/20/2006   4/30/2007   6/11/2007
Expiration date
  5/26/2008   5/31/2008   6/30/2009   4/30/2009   12/31/2009
Counterparties
  Goldman Sachs   Wells Fargo   Goldman Sachs   Wells Fargo   Goldman Sachs
     These interest rate swap agreements have the effect of reducing the amount of our debt exposed to variable interest rates from $530.4 million to $205.4 million. For the 12-month period ending June 30, 2008, for every 1.0% increase in LIBOR we will pay an additional $2.0 million in interest expense and for every 1.0% decrease in LIBOR we will save $2.0 million in interest expense.
     We may consider entering into additional interest rate strategies. However, we have not yet determined what those strategies may be or their possible impact.
ITEM 4.   CONTROLS AND PROCEDURES
     As of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer, based on their evaluation as of the end of the period covered by this Form 10-Q, concluded that our disclosure controls and procedures are effective in timely alerting them to information we are required to include in our periodic reports filed with the SEC.
     During our most recent fiscal quarter, there were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1.   LEGAL PROCEEDINGS
     We are not subject to any legal proceedings other than ordinarily routine litigation incidental to the conduct of our business.
ITEM 1A.   RISK FACTORS
     For information regarding risk factors, please refer to Item 1A in our 2006 annual report on Form 10-K. There have not been any material changes in the risk factors disclosed in our 2006 annual report on Form 10-K.
     Additional information relating to risk factors is described in Management’s Discussion and Analysis of Financial Condition and Results of Operations under Forward-Looking Statements.
ITEM 2.   UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
     None
ITEM 3.   DEFAULTS UPON SENIOR SECURITIES
     None

27


Table of Contents

ITEM 4.   SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
     On June 4, 2007, we held our annual meeting of stockholders at which our stockholders:
    elected Robert L. Antin as a Class II director;
 
    ratified KPMG LLP as our independent auditors; and
 
    approved the VCA Antech, Inc. 2007 Annual Cash Incentive Plan.
     The results of the election of the Class II director was as follows:
                                 
Candidate   Yes Votes   No Votes   Abstain   Broker Non-Vote
Robert L. Antin
    67,052,698             2,440,376        
     The results of the other matters upon which our stockholders voted were as follows:
                                 
Proposal   Yes Votes   No Votes   Abstain   Broker Non-Vote
Ratify KPMG LLP as our independent auditors
    68,942,135       509,900       41,039        
Approve the VCA Antech, Inc. 2007
Annual Cash Incentive Plan
    60,794,944       2,810,171       64,860       5,823,099  
ITEM 5.   OTHER INFORMATION
     None
ITEM 6.   EXHIBITS
     
31.1
  Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
   
31.2
  Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
   
32.1
  Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

28


Table of Contents

SIGNATURE
     Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on August 7, 2007.
             
Date: August 7, 2007
  By:   /s/ Tomas W. Fuller    
 
     
 
Tomas W. Fuller
   
 
      Chief Financial Officer    

29


Table of Contents

EXHIBIT INDEX
     
Exhibit No.   Description
31.1
  Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
   
31.2
  Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
   
32.1
  Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

30


 

EXHIBIT 31.1
Certification of
Chief Executive Officer
of VCA Antech, Inc.
I, Robert L. Antin, certify that:
1.   I have reviewed this quarterly report on Form 10-Q of VCA Antech, Inc.;
 
2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.   Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.   The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  a.   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
  b.   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
  c.   Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
  d.   Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.   The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
  a.   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
  b.   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 7, 2007
     
/s/ Robert L. Antin
   
 
Robert L. Antin
   
Chief Executive Officer
   

 


 

EXHIBIT 31.2
Certification of
Chief Financial Officer
of VCA Antech, Inc.
I, Tomas W. Fuller, certify that:
1.   I have reviewed this quarterly report on Form 10-Q of VCA Antech, Inc.;
 
2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.   Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.   The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  a.   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
  b.   Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
  c.   Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
  d.   Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.   The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
  a.   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
  b.   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 7, 2007
     
/s/ Tomas W. Fuller
   
 
Tomas W. Fuller
   
Chief Financial Officer
   

 


 

      EXHIBIT 32.1
Certification of
Chief Executive Officer & Chief Financial Officer
of VCA Antech, Inc.
     This certification is provided pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and accompanies this quarterly report on Form 10-Q (the “Report”) for the period ended June 30, 2007 of VCA Antech, Inc. (the “Issuer”).
     Each of the undersigned, who are the Chief Executive Officer and Chief Financial Officer, respectively, of VCA Antech, Inc., hereby certify that, to the best of each such officer’s knowledge:
  (i)   the Report fully complies with the requirements of section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and
 
  (ii)   the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Issuer.
Dated: August 7, 2007
         
  /s/ Robert L. Antin    
 
 
 
Robert L. Antin
   
 
  Chief Executive Officer    
 
       
 
  /s/ Tomas W. Fuller    
 
 
 
Tomas W. Fuller
   
 
  Chief Financial Officer